Stephen K. Tahir

AbbVie (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

33h-index12.3kcitations93works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cell death mechanisms and regulation(34), Cancer therapeutics and mechanisms(25), Lung Cancer Research Studies(20), Synthesis and Characterization of Heterocyclic Compounds(13), Peptidase Inhibition and Analysis(12)

Publications93 total

Targeting tumor intrinsic TAK1 engages TNF-α-driven cell death through distinct mechanisms and enhances cancer immunotherapy
Cell Death and Disease·2025Open Access
Supplementary Table S3 from Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains
2023Open Access
Data from Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains
2023Open Access
Supplementary Figure 2 from The Bcl-2/Bcl-X<sub>L</sub>/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figure 1 from The Bcl-2/Bcl-X<sub>L</sub>/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains
2023Open Access
Supplementary Table 1, Figure Legends 1-2 from The Bcl-2/Bcl-X<sub>L</sub>/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table 1, Figure Legends 1-2 from The Bcl-2/Bcl-X<sub>L</sub>/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from The Bcl-2/Bcl-X<sub>L</sub>/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table S3 from Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains
2023Open Access
Supplementary Figure 2 from The Bcl-2/Bcl-X<sub>L</sub>/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table S2 from Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains
2023Open Access
Supplementary Figures 1-3 from Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
2023Open Access
Supplementary Figures 1-3 from Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
2023Open Access
Supplementary Figure Legends from Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
2023Open Access
Data from Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
2023Open Access
Supplementary Figure Legends from Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
2023Open Access
Supplementary Table S2 from Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains
2023Open Access
Data from The Bcl-2/Bcl-X<sub>L</sub>/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figure 1 from The Bcl-2/Bcl-X<sub>L</sub>/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Saul H. Rosenberg(27), Haichao Zhang(23), Morey L. Smith(21), Steven W. Elmore(17), Sha Jin(17), Joel Johansson(16), Paul Nimmer(14), Darren C. Phillips(14), Andrew J. Souers(13), Peter Kovar(13), John Xue(13), Michael J. Mitten(11), Kennan C. Marsh(10), Anatol Oleksijew(9), Xiao Yu(9), Shi‐Chung Ng(9), Milan Bruncko(8), Stephen W. Fesik(8), Chris Tse(8), David J. Frost(8)